Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

In this Phase II study, an investigational monoclonal antibody to calcitonin gene-related peptide (LY2951742) was associated with a reduction in the number of migraine headache days per 28 day period vs. placebo (least-squares mean difference −1.2, 90% CI −1.9 to −0.6; p=0.0030).